Self-Injection Market Size to be Worth USD 181.4 Billion by 2035; Market is Driven by the Rapidly Growing Healthcare Expenditure Globally

Self-injection is the process of injecting a drug or other substance into the body. Rising number of patient preference toward self-administration, increasing cases of hormonal diseases & cancer cases, availability of affordable self-injections, ongoing R&D activities, rising healthcare expenditure, rising popularity of home treatment, and others are the factors contributing to the self-injection market growth.

Self-Injection Market Segmentation Analysis:

By Product	Needle Free Injectors, Auto Injectors, Pen Injectors, wearable Injectors, and Others
By Usability	Disposable and Reusable
By Application	Cancer, Autoimmune Disorders, Hormonal Disorders, Pain Management, and Others
By End-Users	Hospital, Specialty Clinics, and Others

Self-Injection Market Report Highlights:

• By 2035, the market is forecasted to abound at USD 181.4 Billion.
• In 2024, the self-injection market size was at USD 60.67 Billion.
• Target market is accelerating at a CAGR of 12.8%.
• North America held the largest self-injection market share in 2024.
• Asia Pacific is expected to be the fastest-growing region in the market during the forecast period.
• By product, the needle free injectors segment is expected to dominate the market.
• Under usability, disposable is the leading segment in the market.
• Based on application, the cancer segment holds the largest target market share.
• The hospital end-user segment is expected to grow with the highest CAGR during the forecast period.

Self-Injection Market Dynamics:

Growth Factor	Challenge Factor	Market Trend
Rising Chronic Cases Diseases	Limitations Related with Self-Injection	Surging Use of Needle-Free Self-Injection

Self-Injection Market Key Highlights:

• In March 2024, according to a recent announcement, the FDA has approved a new single-dose, pre-filled delivery device, named SeflJect injector, to be used for Acthar Gel (repository corticotropin injection; Mallinckrodt), a treatment indicated for various number of chronic and acute inflammatory and autoimmune conditions, including multiple sclerosis (MS).
• In April 2021, Novartis announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved U.S. indications. 1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.

Self-Injection Market Report Analysis:

Steps for Self-Administration of Injection –

• Wash and dry hands with soap and water
• Clean the area of skin you intend to inject with an alcohol wipe
• Hold the syringe in your dominant hand with the barrel of the syringe between your fingers and your thumb on the plunger
• With your other hand pinch an area of skin between your fingers to create a lump
• Insert the needle all the way into the skin
• Press down the plunger while keeping the needle still
• Use the markings on the barrel to give the amount you have been instructed to
• Remove the needle at the same angle
• Dispose of the needle in the sharps box
• Wipe the area with a piece of gauze

Browse ∼40 market data tables and ∼36 figures through ∼167 slides and in-depth TOC on “Self-Injection Market Size, Share, By Product (Needle Free Injectors, Auto injectors, Pen Injectors, and Wearable Injectors), Usability (Disposable, and Reusable), Usability (Cancer, Autoimmune Disorders, Hormonal Disorders, Pain Management, and Others), End-Users (Hospital, Specialty Clinics, and Others), and Region - Trends, Analysis, and Forecast till 2035”

For more insights into the Self-Injection Market and its future trends, visit the lin: https://www.prophecymarketinsights.com/market_insight/self-injection-market-5754

Self-Injection Market Competitive Landscape:

The leading players operating in the market include BD, YPSOMED, West Pharmaceutical Services, Inc., Haselmeier, NuGen Medical Devices, Owen Mumford Limited, SHL Medical, PFIZER INC., Amgen Inc., Insulet Corporation, Halozyme, Inc., Apikos Pharma & Penardo Biotech Pvt. Ltd., Hindustan Syringes & Medical Devices Ltd., and GSK PLC.

Company Name	BD
Headquarter	Franklin Lakes, New Jersey, U.S.
CEO	Tom Polen
Employee Count (2024)	75,000 Employees